Author: PharmaSignal News Desk

Amneal FDA warning highlights use of contaminated bags in sterile injectable drugs, impacting quality control.

Roche CE mark Contivue advances Susvimo for nAMD in Europe, potentially benefiting 1.7 million people.

Gilead AI manufacturing hub breaks ground in US, creating over 3,000 jobs and boosting biopharma innovation.

OMass Genentech collaboration targets inflammatory bowel disease with a $400 million deal, leveraging OdyssION platform.

Biohaven Vyglxia FDA approval leads to launch preparations, with a patient hub and sales force ready.

FDA approves Leqembi Iqlik as a weekly subcutaneous injection for Alzheimer’s, enhancing patient convenience and safety.

Avadel licenses sleep drug for $20M upfront, expanding its portfolio with XWPharma’s valiloxybate.

Gilead HIV drug prices increase significantly, while Novartis enters a $5.2 billion licensing deal with Argo Biopharmaceutical.

Enveda Biosciences funding reaches $300M to develop drugs for immune and obesity conditions, including atopic dermatitis and asthma.

FDA ultra-rare disease drugs review pathway targets conditions affecting fewer than 1,000 people in the U.S.